Roche’s oral obesity drug leads to weight loss in early study

LONDON — Roche on Wednesday reported optimistic early information from one other of the weight problems drug candidates that it picked up by way of an acquisition late final yr, bolstering the case it may change into a participant within the aggressive weight-loss drugs subject. 

The corporate mentioned its once-daily tablet, known as CT-996, led to a placebo-adjusted common weight lack of 6.1% after 4 weeks in sufferers with weight problems who didn’t have diabetes. The figures reported Wednesday got here from an preliminary evaluation of a Section 1 trial, however with a lot consideration on the booming obesity-medicine enviornment, they lifted Roche shares by 5% in early buying and selling.

Roche mentioned it will advance CT-996 right into a Section 2 research.